larotrectinib
Generic: LAROTRECTINIB SULFATE·Brand: VITRAKVI, Vitrakvi·Code: LOXO-101
larotrectinib: sourced relationships with 2 companies · 1 clinical trial tracked.
larotrectinib evidence translation
What we can confirm
1 tracked trial
What it means
More than one company relationship is source-backed. Until you choose one, AI stays drug-only and does not guess ownership.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about larotrectinib, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 0 study sponsors
Related indications
cancerunresectable or metastatic solid tumors with NTRK-fusion proteinsBreast CarcinomaCervical CarcinomaColorectal CarcinomaEndometrial CarcinomaGliomaLung Carcinoma
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (2)
| Company | Dated record stage |
|---|---|
| ARRAY BIOPHARMA INC (ARRY) | Phase 2 |
| LOXO ONCOLOGY, INC. (LOXO) unresectable or metastatic solid tumors with NTRK-fusion pro… | BLA Filed |
Clinical Trial Registry Records (1)
Molecular Analysis for Therapy Choice (MATCH)
Primary endpoint: Objective response rate (ORR)
Interventionalopen6,452 targetStarted 2015-08Completion 2026-1250 sites · United StatesNational Cancer Institute (NCI)
Frequently asked questions
Which companies have sourced relationships with larotrectinib?
larotrectinib has dated SEC/FDA relationship records for ARRAY BIOPHARMA INC, LOXO ONCOLOGY, INC..
How many clinical trials involve larotrectinib?
BioSniper tracks 1 clinical trial involving larotrectinib.